Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BCAB 
Bioatla Inc (BCAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BCAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.98% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.50M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 4 | Beta 0.91 | 52 Weeks Range 0.24 - 2.52 | Updated Date 09/15/2025 |
52 Weeks Range 0.24 - 2.52 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -574.72% |
Management Effectiveness
Return on Assets (TTM) -82.52% | Return on Equity (TTM) -813.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33341358 | Price to Sales(TTM) 4.14 |
Enterprise Value 33341358 | Price to Sales(TTM) 4.14 | ||
Enterprise Value to Revenue 3.03 | Enterprise Value to EBITDA 0.31 | Shares Outstanding 58721600 | Shares Floating 45424084 |
Shares Outstanding 58721600 | Shares Floating 45424084 | ||
Percent Insiders 10.58 | Percent Institutions 29.76 |
Upturn AI SWOT
Bioatla Inc
Company Overview
History and Background
BioAtla, Inc. was founded in 2011 and is a global biotechnology company focused on developing conditionally active antibody therapeutics for solid tumors. They are using their proprietary Conditionally Active Biologics (CAB) technology.
Core Business Areas
- CAB Antibody Development: BioAtla's primary focus is the development of CAB antibodies that are designed to be activated in the tumor microenvironment, minimizing off-target toxicity.
- Therapeutic Pipeline: The company is advancing a pipeline of CAB antibody drug conjugates (ADCs) and other therapeutic candidates targeting various solid tumors.
Leadership and Structure
BioAtla is led by a team with experience in antibody engineering and drug development. The company's structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- BA3011 (CAB-AXL-ADC): BA3011 is a CAB-AXL-ADC targeting AXL-expressing tumors. Currently in clinical trials. Market share data is not yet available due to clinical stage. Competitors include companies developing AXL-targeting therapies.
- BA3021 (CAB-ROR2-ADC): BA3021 is a CAB-ROR2-ADC in clinical trials. Market share data is not yet available due to clinical stage. Competitors include companies developing ROR2-targeting therapies.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and focuses on developing new therapies for various diseases. The immuno-oncology space, where BioAtla operates, is rapidly growing with significant investment and innovation.
Positioning
BioAtla is positioned as a leader in developing conditionally active antibodies. Their competitive advantage lies in their CAB technology platform, which aims to improve the safety and efficacy of antibody therapeutics.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is substantial, expected to reach hundreds of billions of dollars. BioAtla is targeting specific tumor types, positioning itself within this large market by offering unique CAB antibody therapies.
Upturn SWOT Analysis
Strengths
- Proprietary CAB technology platform
- Pipeline of novel antibody therapeutics
- Experienced leadership team
- Focus on addressing unmet medical needs in oncology
Weaknesses
- Clinical stage company with no approved products
- High R&D expenses
- Dependence on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
Opportunities
- Potential for strategic collaborations and partnerships
- Expansion of CAB technology to other therapeutic areas
- Advancement of pipeline candidates through clinical development
- Market approval and commercialization of CAB antibodies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- TGTX
Competitive Landscape
BioAtla competes with companies developing novel cancer therapies, particularly those targeting similar tumor microenvironments or using antibody-based approaches. BioAtla's CAB technology may offer a differentiation in terms of safety and efficacy, but this needs to be proven in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: BioAtla's historical growth is characterized by the advancement of its technology platform and therapeutic pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include advancing its CAB-ADC programs into later-stage clinical trials and seeking strategic partnerships.
Summary
BioAtla is a development-stage biotechnology company with a promising conditionally active antibody technology. Their CAB platform has the potential to offer safer and more effective cancer therapies. However, the company faces risks associated with clinical trials, regulatory approvals, and competition. Successful advancement of their pipeline is crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioAtla's SEC Filings
- Company Website
- Financial News Outlets
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioatla Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-12-16 | Co-Founder, CEO & Chairman Dr. Jay M. Short Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.bioatla.com |
Full time employees 61 | Website https://www.bioatla.com | ||
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.